APA

Bendell J. C., Zakari A., Lang E., Waterhouse D., Flora D., Alguire K., McCleod M., Peacock N., Ruehlman P., Lane C. M., Earwood C. & Shih K. (20170206). A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. : Cancer investigation.

Chicago

Bendell Johanna C, Zakari Ahmed, Lang Evan, Waterhouse David, Flora Douglas, Alguire Kathryn, McCleod Michael, Peacock Nancy, Ruehlman Peter, Lane Cassie M, Earwood Chris and Shih Kent. 20170206. A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. : Cancer investigation.

Harvard

Bendell J. C., Zakari A., Lang E., Waterhouse D., Flora D., Alguire K., McCleod M., Peacock N., Ruehlman P., Lane C. M., Earwood C. and Shih K. (20170206). A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. : Cancer investigation.

MLA

Bendell Johanna C, Zakari Ahmed, Lang Evan, Waterhouse David, Flora Douglas, Alguire Kathryn, McCleod Michael, Peacock Nancy, Ruehlman Peter, Lane Cassie M, Earwood Chris and Shih Kent. A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. : Cancer investigation. 20170206.